Advertisement
AMGN vs BIIB
Which Stock Would AI Choose? Amgen (AMGN) vs. Biogen (BIIB) Stock Comparison
Key Takeaways
- Amgen maintains a larger market capitalization and diversified portfolio across oncology, cardiovascular, and inflammation, while Biogen focuses on neurology and immunology with ongoing portfolio shifts.
- In recent weeks, Amgen shares experienced a sharp pullback of approximately 15% over five trading days amid spillover from a competitor’s Phase 3 trial setback in the Lp(a) cardiovascular space.
- Biogen raised its full-year 2026 revenue outlook to mid-single-digit growth following acquisitions such as RayThera and continued progress in its growth portfolio.
- Amgen reported robust Q2 2026 results with revenue exceeding $10 billion and raised full-year guidance, supported by strong performance from key products including Repatha and IMDELLTRA.
- Both companies operate in the biotechnology sector with exposure to regulatory and clinical trial risks, though Amgen’s scale provides greater earnings stability compared with Biogen’s turnaround dynamics.
- Relative momentum favors Biogen’s year-to-date gains, while Amgen offers dividend income and broader commercial diversification amid recent market volatility.
Introduction
Amgen and Biogen represent two established biotechnology companies with overlapping yet distinct therapeutic focuses. This comparison examines their business models, recent stock performance, and market positioning to assist investors and traders evaluating relative opportunities within the healthcare sector. Portfolio managers seeking exposure to large-cap biotech stability alongside those monitoring neurology and immunology pipelines may find the analysis relevant for assessing risk-adjusted positioning in the current environment.
Amgen Overview and Recent Performance
Amgen develops and commercializes therapies in oncology, cardiovascular disease, inflammation, and rare conditions. In recent market activity, the stock faced pressure following a competitor’s unsuccessful Phase 3 Lp(a) cardiovascular outcomes trial, which raised questions about Amgen’s similar olpasiran program and contributed to a multi-day decline. Despite the short-term volatility, the company delivered strong second-quarter 2026 results with revenue above $10 billion and raised full-year guidance, reflecting solid execution across growth drivers such as Repatha and IMDELLTRA. Positive Phase 3 data for IMDELLTRA in small cell lung cancer further supported sentiment in recent weeks.
Biogen Overview and Recent Performance
Biogen focuses on neurology and, increasingly, immunology through marketed products and pipeline assets. Recent developments include completion of the RayThera acquisition and an upward revision to full-year 2026 revenue guidance, shifting expectations from decline to mid-single-digit growth. The company continues to navigate declines in its legacy multiple sclerosis franchise while advancing growth products and late-stage candidates. Stock performance in recent weeks has reflected steady investor response to these strategic moves and pipeline updates, with shares trading in a relatively stable range compared with broader sector movements.
Trending AI Robots
Tickeron maintains a curated section highlighting its most relevant AI trading bots for prevailing market conditions. While hundreds of bots trade thousands of tickers across varied styles, strategies, timeframes, and performance profiles, only those demonstrating strong suitability for current environments appear in the Trending AI Robots listing. Users can review detailed statistics, historical results, and ticker coverage to identify bots aligned with their objectives. The platform offers transparent metrics that allow evaluation of risk-adjusted outcomes before deployment.
Head-to-Head Comparison
Amgen operates with greater scale and revenue diversification, generating approximately $38 billion in trailing twelve-month revenue compared with Biogen’s roughly $10 billion. Growth drivers for Amgen include established franchises in cardiovascular and oncology, while Biogen emphasizes neurology assets such as Leqembi alongside immunology expansion via acquisitions. Recent momentum shows Amgen contending with clinical spillover effects, whereas Biogen has benefited from outlook upgrades. Risk factors include pipeline execution for both, with Amgen facing potential cardiovascular program uncertainty and Biogen managing multiple sclerosis erosion. Sector exposure remains concentrated in biotechnology, though Amgen’s larger market capitalization and dividend yield provide relative stability versus Biogen’s higher-beta turnaround profile.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative positioning, Tickeron’s AI models currently assign a modestly higher probabilistic preference to Amgen. The company’s broader revenue base, recent guidance raises, and dividend support offer a more resilient profile amid clinical volatility, though Biogen’s acquisition-driven pipeline momentum warrants continued monitoring for potential shifts in relative attractiveness.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and BIIB is a Buy.
AMGN | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 29 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 9 | 100 | |
SMR RATING 1..100 | 15 | 84 | |
PRICE GROWTH RATING 1..100 | 40 | 33 | |
P/E GROWTH RATING 1..100 | 27 | 5 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (8) in the Biotechnology industry is significantly better than the same rating for BIIB (78). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's Profit vs Risk Rating (9) in the Biotechnology industry is significantly better than the same rating for BIIB (100). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for BIIB (84). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (33) in the Biotechnology industry is in the same range as AMGN (40). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
BIIB's P/E Growth Rating (5) in the Biotechnology industry is in the same range as AMGN (27). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | BIIB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 68% | N/A |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 53% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 64% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 47% | 2 days ago 64% |
| Advances ODDS (%) | 4 days ago 61% | 5 days ago 59% |
| Declines ODDS (%) | 2 days ago 47% | 2 days ago 68% |
| BollingerBands ODDS (%) | 2 days ago 63% | N/A |
| Aroon ODDS (%) | 2 days ago 45% | 2 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while BIIB’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- BIIB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while BIIB’s TA Score has 4 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 4 bearish.
- BIIB’s TA Score: 4 bullish, 2 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +0.30% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -1.56% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -3.39%. For the same industry, the average monthly price growth was -8.55%, and the average quarterly price growth was +8.33%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
BIIB is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-3.39% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | -1.35% | ||
| AMGN - BIIB | 49% Loosely correlated | -3.38% | ||
| AZN - BIIB | 49% Loosely correlated | -2.33% | ||
| PFE - BIIB | 48% Loosely correlated | -1.40% | ||
| MRK - BIIB | 46% Loosely correlated | -1.03% | ||
| ABBV - BIIB | 41% Loosely correlated | -0.63% | ||
More | ||||